Barboy Oren, Katzenelenbogen Yonatan, Shalita Rotem, Amit Ido
Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
Cancer Discov. 2023 Jul 7;13(7):1546-1555. doi: 10.1158/2159-8290.CD-23-0010.
Chimeric antigen receptor (CAR) T therapies hold immense promise to revolutionize cancer treatment. Nevertheless, key challenges, primarily in solid tumor settings, continue to hinder the application of this technology. Understanding CAR T-cell mechanism of action, in vivo activity, and clinical implications is essential for harnessing its full therapeutic potential. Single-cell genomics and cell engineering tools are becoming increasingly effective for the comprehensive research of complex biological systems. The convergence of these two technologies can accelerate CAR T-cell development. Here, we examine the potential of applying single-cell multiomics for the development of next-generation CAR T-cell therapies.
Although CAR T-cell therapies have demonstrated remarkable clinical results in treating cancer, their effectiveness in most patients and tumor types remains limited. Single-cell technologies, which are transforming our understanding of molecular biology, provide new opportunities to overcome the challenges of CAR T-cell therapies. Given the potential of CAR T-cell therapy to tip the balance in the fight against cancer, it is important to understand how single-cell multiomic approaches can be leveraged to develop the next generations of more effective and less toxic CAR T-cell products and to provide powerful decision-making tools for clinicians to optimize treatment and improve patient outcomes.
嵌合抗原受体（CAR）T细胞疗法有望彻底改变癌症治疗方式。然而，主要在实体瘤治疗方面的关键挑战仍在阻碍这项技术的应用。了解CAR T细胞的作用机制、体内活性及临床意义对于充分发挥其治疗潜力至关重要。单细胞基因组学和细胞工程工具在复杂生物系统的全面研究中变得越来越有效。这两种技术的融合能够加速CAR T细胞的研发。在此，我们探讨应用单细胞多组学技术开发下一代CAR T细胞疗法的潜力。
尽管CAR T细胞疗法在癌症治疗中已展现出显著的临床效果，但其对大多数患者和肿瘤类型的有效性仍然有限。正在改变我们对分子生物学理解的单细胞技术为克服CAR T细胞疗法的挑战提供了新机遇。鉴于CAR T细胞疗法在对抗癌症斗争中具有扭转战局的潜力，了解如何利用单细胞多组学方法开发更有效、毒性更低的下一代CAR T细胞产品，并为临床医生提供强大的决策工具以优化治疗并改善患者预后至关重要。
